GBS is an ACUTE polyneuropathy (peripheral nervous system). Symmetrical in distribution. The onset is often over about 4 weeks and recovery often begins 2 weeks after progression has completed.
It can be a VERY serious disease. With the near-eradication of polio, GBS has become the most common cause of acute flaccid paralysis in developed countries. This has obvious implications in the ICU. 1/4 of patients will require IPPV. 3-11% will die of GBS complications.
To be specific, it's a heterogeneous disorder that involves the classical DEMYELINATING type of inflammatory polyradiculoneuropathy (AIDP) + the more rapid and usually less benign motor-sensory axonal forms (AMAN, AMSAN) and the anti-GQ1b spectrum of Miller-Fisher syndrome (MFS)
MFS is a more rare variant of GBS and usually presents with at least 2 of the following features: ataxia, areflexia, and ophthalmoplegia. MFS is commonly associated with the involvement of the lower cranial and facial nerves and does not usually involve motor weakness of limbs.
MFS variants including weakness of the respiratory system and limbs have been described. Another variant of MFS is Bickerstaff brainstem encephalitis (BBE) and involves altered consciousness, ataxia, ophthalmoparesis, and paradoxical hyperreflexia. ncbi.nlm.nih.gov/books/NBK50771…
GBS-like disease has been described in other medical conditions associated with acquired immunodeficiencies, transplantations, lymphomas, and biological treatments.
If we consider meningitis - we know the morphology of the 'typical' samples - but in GBS, it is the protein count that interests us... as well as some other things
Albuminocytological dissociation (ACD), the classical alteration of the CSF in GBS was described in the original paper by Guillain, Barré and Strohl. This is an increased total protein concentration with normal total nucleated cell count.
ACD occurs in diseases that alter the blood-brain barrier, increase the production of protein or obstruct the flow of CSF.
During acute GBS, characteristic findings on CSF analysis include ACD = CSF protein (>0.55 g/L) without an elevation in white blood cells. The increase in CSF protein is thought to reflect the widespread inflammation of the nerve roots + incr BBB permeability.
CSF should be acellular. Protein levels may be normal during the 1st week of the illness, but the majority will have an ^protein if measured 2 or 3 weeks later. Incr CSF protein concentration in GBS has been mainly associated with increased permeability of the blood-CSF barrier.
This excellent flow diagram characterises the complex processes that contribute to GBS - including causes and therefore, things to test for... link.springer.com/chapter/10.100…
BIG exclusions of cause would be: Campylobacter jejuni enteritis (25-50% - so ask about BBQs!), Viral (CMV, EBV, Hepatitises, HIV, Flu, Zika, Chikungunya), Mycoplasma and VACCINATIONS such as flu/rabies.
Campylobacter jejuni (CJ) infections do = 25-50% of causes, but only <1% of those infected with CJ develop GBS symptoms. It causes auto-antibodies resulting from molecular mimicry (e.g. glycans expressed on bacterial lipooligosaccharides (LOS))
So.... GBS affects peripheral nerves, primarily spinal and cranial nerve roots. Autonomic nerves sometimes affected - so look for autonomic signs - BP/HR etc.
TWO immune-injury pathologies at play: 1. Myelin sheath and related Schwann-cell components are targeted in acute inflammatory demyelinating polyneuropathy. 2. Membranes on the nerve axon are targeted in acute motor axonal neuropathy
GBS is mainly a humoral, rather than T-cell-mediated disorder, at least in the progressive phase of nerve injury. Recovery involves the dampening of the immune response and endogenous repair of nerves. litfl.com/guillain-barre…
The MECHANISM of cause affects the clinical phenotype and prognosis: CJ infections are usually associated with a pure motor axonal form of GBS, more severe limb weakness, and a serological antibody response directed against GM1 and GD1a gangliosides
For severe GBS, the relative risk of improving one or more functional grades by 4 weeks after PE treatments was 1.64 (95% CI 1.37 to 1.96). Treatment also significantly reduced the number of patients requiring mechanical ventilation, shortened the time to extubation.
PLEX increased the number of patients achieving full strength at 1 year, and reduced the number of patients experiencing severe sequelae at 1 year.
These studies also demonstrated that treatment within 7 days is the most effective and that patients with mild GBS (able to ambulate at the time of treatment) still benefit from PE. pubmed.ncbi.nlm.nih.gov/9066350/
ICU considerations include intubation when the patient experiences muscular respiratory failure. Remember they will require full ventilation due to lack of triggering breaths. It is unlikely that a quick-wean will occur - so have a slow approach. litfl.com/guillain-barre…
Sometimes the prodrome can be unclear - so consider multiple factors. Sometimes, the initial presentation is muscular or radicular PAIN (back pain) which in 1/3 of cases precedes the weakness.
Ensure you have all the necessary investigations complete:
POST-ICU CARE is a MAJOR consideration. It requires meticulous rehab and specialist care. There is significant mortality after discharge from ICU. jnnp.bmj.com/content/85/10/…
In the UK, the mortality rate in ICU is 7.7% but the in-hospital mortality rate after ICU step-down is 16.7%. pubmed.ncbi.nlm.nih.gov/17881005/
• • •
Missing some Tweet in this thread? You can try to
force a refresh
What were the most impactful non-COVID papers over the past 2 years? Let's delve in and take a look. #SOA21
Finally an opportunity to not talk about COVID! #SOA21
TOMAHAWK - immediate vs delayed/selective angio. 3 years to conduct the trial in 31 ICUs. 554 patients. 'Worse' survival in immediate angiograph? Not SS, but close... #SOA21
We've looked at bats for a long time.... #SOA21 They have strong interferon responses, but not strong inflammation....
So what happens instead? #SOA21 They will tolerate high levels of viraemia with little symptoms. Bats are old... 65million years ago - they appeared at the end of the dinosaurs! They are far longer lived that other mammals. Senescence is late - more towards end of life.
Organophosphate poisoning, toxicology, dengue, snake bites and malaria.... sure what could go wrong? #SOA21@ICS_updates Drs. Chacko, Yacoub, Bhaumik and Dondorp tell us more.... 🧵👇😘
Biomarker guided abx treatments in sepsis. We catch up with Drs/Profs: Paul Dark, Stacy Todd, Enitan Carrol, Jonathan Sandoe and Matthew Stevenson on this large area of research @ICS_updates#SOA21
So, do biomarkers have any utility in guiding abx use in sepsis? We can measure, usually, these ones fairly easily: #SOA21
In around 2014, commissioned review in PCT. Seemed to suggest a shorter duration in abx use when PCT used.... tenuous data though. #SOA21 Low quality. Little evidence from UK... how does this fit into NHS practice in the realms of stewardship?
There's been a lot that's gone on over the past few years that's exposed the well known 'darker' side of social media. Traditional paradigms of knowledge dissemination have changed (if not disappeared). Much higher tech-savy population. #SOA21
This has democratised the discussion space to an extent. It allows for *anybody* (lit. anybody) to get involved. #SOA21
Is COVID-19 hyperinflammation, or a cytokine storm in a teacup? @DrPujaMehta1 's fab talk from #SOA21 today!
Main Q = "Hyperinflation contributing to worse outcomes for some patients with COVID-19" - clinical similarities to sHLH seen. Viruses are the most common trigger of sHLH. Early reports from China suggested cytokine profile was similar to sHLH in terms of COVID severity. #SOA21
We now know some things work and some things don't.... in certain populations. #SOA21